Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Ajay Chari, MD, professor of medicine, director of Clinical Research, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, discusses findings from the phase 1/2 MonumenTAL-1 trial (NCT04634552) investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Data on 2 different recommended phase 2 doses of talquetamab were presented at the 2022 ASH Annual Meeting.

When administered at a 0.4 mg/kg weekly dose, talquetamab elicited an overall response rate (ORR) of 74.1%, according to Chari. The 0.8 mg/kg weekly dose of the agent produced an ORR of 73.1%. Notably, 31.1% of patients in the 0.4-mg/kg cohort and 28.9% of those in the 0.8-mg/kg cohort had high-risk cytogenetics, Chari explains.

Historically, an ORR of 20% or better could be enough to support the approval of an agent for the treatment of patients with this disease, Chari says. Talquetamab represents another promising agent in the era of T-cell redirection that could deliver durable remissions to patients who previously had no options, Chari concludes.

Related Videos
Related Content